BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 2, 2013
View Archived Issues
AnaptysBio adds new combination therapies to its immunotherapy portfolio
Read More
Galera initiates phase I head and neck cancer trial with new product
Read More
Pilocarpine/tolterodine fixed-dose combination is well tolerated at increased total daily doses
Read More
Researchers at Allergan disclose novel FPR2/ALX receptor ligands
Read More
Millennium Pharmaceuticals prepares new ubiquitin-activating enzyme inhibitors
Read More
Fedovapagon tested as potential therapy for nocturia associated with BPH
Read More
Teva Pharmaceutical begins phase I CEP-37440 study
Read More
Research Triangle Institute discloses novel CB1 receptor antagonists
Read More
Meda to acquire Acton Pharmaceuticals
Read More
Arizona State University synthesizes new agents for mitochondrial disorders
Read More
Researchers at IGM Biosciences patent novel antigen binding proteins
Read More
Ophthotech opens enrollment for phase III Fovista program
Read More
Subcutaneous Herceptin approved in Europe
Read More
Teva will not proceed with Nuvigil regulatory filing in depression following trial results
Read More
Debiopharm initiates phase I Debio-1347 trial
Read More
Aubagio approved in Europe for relapsing-remitting MS
Read More
RaQualia-Interprotein collaboration yields protein-protein interaction inhibitor hits
Read More
SBI Pharmaceuticals plans phase II study for chemotherapy-induced anemia
Read More
AZD-7507 demonstrates good oral pharmacokinetic profile in vivo
Read More
AesRx cleared to begin phase II trial of AES-103 in sickle cell disease
Read More
Antihypertensive, cardioprotective activity of intestinal NHE-3 blockade with SAR-218034
Read More
The University of Tsukuba presents novel agents for cancer
Read More
UCB Canada announces launch of rotigotine patch for patients with Parkinson's disease
Read More